Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.
Ankit Kansagra, MD, assistant professor, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses remaining questions with CAR T-cell therapy in multiple myeloma.
CAR T-cell therapy has shown unprecedented activity in multiple myeloma, explains Kansagra.
Combining CAR T-cell therapy with other drugs may improve T-cell persistence; however, investigational combinations are still in preclinical stages of research, says Kansagra. CAR T-cell therapy could also show enhanced responses earlier on in treatment. As such, several trials are evaluating CAR T-cell therapy in the early relapse setting rather than in heavily pretreated patient populations.
Furthermore, little is known about the optimal treatment for patients who progress on CAR T-cell therapy. This is an area of unmet need that requires further investigation, concludes Kansagra.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.